AGT and diabetic kidney disease: Additionally, GLP-1 RAs have shown potential in mitigating inflammation in diabetic kidney disease by inhibiting angiotensin II signaling, downregulating the receptor for advanced glycation end products, attenuating myelopoiesis, and promoting M2 macrophage polarization in mouse models [65, 66].